Dec 2 (Reuters) - GlaxoSmithKline on Thursday said
that a pre-clinical analysis of the antibody-based COVID-19
therapy it is developing with U.S. partner Vir has
indicated that the drug also works against the new Omicron
variant.
Further tests will be carried out on the sotrovimab therapy
to firm up the results, GSK said in a statement.
(Reporting by Ludwig Burger
Editing by David Goodman
)